Clinical trials: Blood-Borne Infections
Hepatitis C Infection, Hepatitis C Virus
A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults
This study will evaluate the safety and efficacy of ombitasvir/paritaprevir/ ritonavir and dasabuvir administered for 8 weeks in treatment-naïve participants with genotype 1b (GT1b) hepatitis C virus (HCV).
- Trial name
- GARNET (NCT02582632)
- Testing
- ombitasvir/paritaprevir/ritonavir, dasabuvir
- Volunteers
- 166 people
- Sponsor
- AbbVie
HIV Positive
Antioxidant in Patients HIV+ Supplemented With Microencapsulated of Red Pomegranate
Human immunodeficiency virus (HIV) infection continues to be a pandemic, Mexico has around 184,000 people infected by this virus.
- Trial name
- NCT03531749
- Testing
- HIV+ MRPJ, HIV+ ascorbic acid
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Universidad Autónoma del Estado de Hidalgo
Hepatitis C
C Tracker, Hepatitis C, Care & Collaboration - Patient Reported Outcomes Survey Study
Today's mobile devices (especially smartphones) are powerful ways to communicate new information to medical researchers. For this study, researchers at Boston Children's Hospital are asking people with hepatitis C to make use of…
- Trial name
- CTracker (NCT02568540)
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- Boston Children's Hospital
HIV Infections
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
The purpose of this study was to examine the pharmacokinetics, safety, and tolerability of abacavir/dolutegravir/lamivudine dispersible and immediate release tablets in children living with HIV less than 12 years of age.
- Trial name
- NCT03760458
- Testing
- Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets, Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release)
- Where
- 14 sites in United States, Botswana and 2 more
- Volunteers
- 57 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Immunogenicity of COVID-19 Vaccination in PLWH
Various facts support the study of COVID-19 vaccine immunogenicity in People Living With HIV (PLWH) at this time: (1) Many PLWH in Canada will be eligible to receive COVID-19 vaccination as they are in a high priority risk group…
- Trial name
- HIV-COV (NCT04894448)
- Testing
- COVID-19 Vaccine
- Where
- 3 sites in Canada
- Volunteers
- 500 people
- Sponsor
- CIHR Canadian HIV Trials Network
Hepatitis B, Chronic
Entecavir Plus Adefovir in Lamivudine-Resistant Patients
Combination therapy with entecavir 1.0 mg plus adefovir 10 mg has superior antiviral activity compared with either entecavir monotherapy 1.0 mg or adefovir 10 mg plus lamivudine 100 mg in Chinese adults with lamivudine-resistant…
- Trial name
- NCT00986778
- Testing
- Lamivudine, Entecavir, Adefovir
- Sponsor
- Bristol-Myers Squibb
HIV/AIDS Treatment, HIV Infections
Lopinavir/Ritonavir (Kaletra) PK in Children
The objective of this study is to compare the pharmacokinetics of lopinavir tablets administered to pediatric patients as either whole or crushed tablets.
- Trial name
- NCT00810108
- Testing
- lopinavir/ritonavir (Kaletra®) tablets
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Chronic Hepatitis c
'Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat'
Objective: To coordinate active tracing of chronic hepatitis C patients lost to follow-up to inform them about there disease severity and treatment options.
- Trial name
- Track&Trace (NCT03088917)
- Where
- Netherlands
- Volunteers
- 106 people
- Sponsor
- Radboud University Medical Center
HIV/AIDS
Improving Health Outcomes for Women Living With HIV
This study will develop and conduct a trans-specific peer navigation intervention in Brazil, which integrates the I-Care approach developed in South Africa with the Model of Gender Affirmation (GA), developed by the investigators…
- Trial name
- NCT03525340
- Testing
- Peer Navigation
- Where
- Brazil
- Volunteers
- 113 people
- Sponsor
- University of California, San Francisco
HIV Infection
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
Raltegravir is the first marketed strand-transfer inhibitor of HIV-1 that was FDA approved in 2007. It is currently one of the preferred treatment regimens for HIV by the Department of Health and Human Services.
- Trial name
- NCT02302950
- Testing
- raltegravir
- Where
- United States
- Volunteers
- 254 people
- Sponsor
- The University of Texas Health Science Center, Houston
Chronic Hepatitis B
Targeting ANKRD11 Reverses HBV-Specific CD8+ T Cell Dysfunction and Tolerance
Achieving a functional cure for chronic hepatitis B (CHB) is largely hindered by the irreversible functional exhaustion and immune tolerance of hepatitis B virus (HBV)-specific CD8 positive T (CD8+ T) cells.
- Trial name
- NCT07777250
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Beijing Municipal Administration of Hospitals
Chronic Hepatitis B
Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in Chronic Hepatitis B Patients
The aim is to investigate the best treatment regime of PEG-Intron A and lamivudine combination in terms of viral clearance in chronic hepatitis B patients.
- Trial name
- NCT00226447
- Testing
- Pegylated Interferon, Lamivudine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese University of Hong Kong
HIV Infections, Coronary Disease
HIV&HEART Aging Study (12,5 Year Follow up)
The HIV/HEART Aging study (HIVH) is an ongoing, prospective, multicentre trial that was conducted to assess the incidence, the prevalence and the clinical course of cardiovascular diseases (CVD) in HIV-infected patients.
- Conditions
- HIV Infections, Coronary Disease, Myocardial Infarction, HIV Encephalopathy
- Trial name
- HIV&HEART (NCT04156048)
- Where
- 6 sites in Germany
- Volunteers
- 1,809 people
- Sponsor
- University Hospital, Essen
HIV Infection
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
The study will explore the effects of early intensive antiretroviral therapy (ART) with or without a broadly neutralizing antibody (bNAb) on achieving HIV remission (HIV RNA below the limit of detection of the assay) among…
- Trial name
- NCT02140255
- Testing
- Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Nevirapine (NVP), Lopinavir/Ritonavir (LPV/r)
- Where
- 47 sites in United States, Argentina and 11 more
- Volunteers
- 1,120 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients
To characterize the safety and efficacy of fixed doses of MDL 28,574A administered alone and in combination with zidovudine ( AZT ) in patients with asymptomatic or mildly symptomatic HIV infection.
- Trial name
- NCT00002150
- Testing
- Celgosivir hydrochloride
- Where
- 23 sites in United States
- Volunteers
- 200 people
- Sponsor
- Hoechst Marion Roussel
Hepatitis C Virus Infection
Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis
This study is to evaluate the antiviral efficacy, safety, and tolerability of combination therapy with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) + vedroprevir (VDV) ± ribavirin (RBV) for 8 weeks in…
- Trial name
- NCT02226549
- Testing
- LDV/SOF, VDV, RBV
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Gilead Sciences
HIV Infections
A Study to Test the Safety of Recombinant Interleukin-2 (rIL-2) in HIV-Infected Children
The purpose of this study is to determine the safety and maximum tolerated dose (the highest dose that can be given safely) of recombinant Interleukin-2 (rIL-2) in HIV-infected children.
- Trial name
- NCT00000849
- Testing
- Aldesleukin
- Where
- 14 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, HIV Infections
Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis
This study evaluated the safety, tolerability, and pharmacokinetics of the anti-tuberculosis (TB) drugs bedaquiline (BDQ) and delamanid (DLM), alone and in combination, among participants (with or without HIV co-infection) taking…
- Trial name
- NCT02583048
- Testing
- Bedaquiline, Delamanid, Dolutegravir
- Where
- 3 sites in Peru, South Africa
- Volunteers
- 84 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC
To determine the safety of intravenous infusion of ampligen in symptomatic HIV-infected patients at several dose levels, to determine the maximum dose that can be tolerated, and to measure the effects of ampligen on the HIV virus…
- Trial name
- NCT00000735
- Testing
- Ampligen
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Hepatitis C Infection
A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults
The purpose of this study is to evaluate the safety and antiviral activity of 3 direct-acting antiviral agents (DAAs; ABT-450/ritonavir/ABT-267 [ABT-450/r/ABT-267; ABT-267 also known as ombitasvir] and ABT-333 [also known as…
- Trial name
- MALACHITE II (NCT01854528)
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin, Pegylated Interferon a-2a (PegINF)
- Volunteers
- 148 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.